News
-
-
PRESS RELEASE
Jaguar Health Reports Statistically Significant Improvement in Breast Cancer Patients in its Phase 3 OnTarget Trial for its Cancer Supportive Care Drug Crofelemer
Jaguar Health, Inc. announces positive results for crofelemer in breast cancer patients from OnTarget trial, to be presented at an oncology conference with potential for future submissions. Crofelemer also shows promise in IBS-D patients -
-
PRESS RELEASE
Jaguar Health Scientific Advisory Board Member to Share Poster Presentation at American Society of Clinical Oncology (ASCO) Quality Care Symposium About the Methodologies Involved in Designing an Advocate-Led Quality of Life Survey for Cancer Patients and
Jaguar Health, Inc. focuses on cancer supportive care & quality of life for patients. ASCO presentation on methodologies for 'More Than a Diagnosis' survey sponsored by Napo Pharmaceuticals -
-
-
-
PRESS RELEASE
Jaguar Health to Spotlight Company's Commercial Focus on Cancer Supportive Care at American Society for Radiation Oncology (ASTRO) Annual Meeting for FDA-Approved Gelclair Oral Mucositis Product in Advance of October 2024 Gelclair Launch
Jaguar Health's Napo Pharmaceuticals to showcase Gelclair, an FDA-approved oral mucositis prescription product, at ASTRO Annual Meeting. Gelclair offers pain relief and support for cancer patients -
-
